Access to medicines proves a problem for pharma's reputation; a pharma company hits a wall in digital health

Taking stock of the drug industry, from the lab to the medicine chest

April 28, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Covid-19 burnished pharma's reputation among patient groups, but access to medicines is now an issue In the wake of the Covid-19 pandemic, drugmakers saw their reputation burnished among patient groups. That picture has changed. By Ed Silverman STAT+ | Once bullish on digital health, Orexo hits a wall on reimbursement Orexo's careful approach to tech is a stark contrast to the bullish tone the pharma company took when it dove into digital therapeutics. By Mario Aguilar Pennsylvania set to ban supervised drug use sites, in setback for harm reduction A Philadelphia nonprofit says such a site would prevent overdose and death, but lawmakers, led by Democrats, are poised to block the move. By Lev Facher Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser